Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History HALO

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics HALO

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Halozyme Therapeutics Inc

HALO
Current price
56.60 USD -1.11 USD (-1.92%)
Last closed 57.65 USD
ISIN US40637H1095
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 7 101 226 496 USD
Yield for 12 month +2.72 %
1Y
3Y
5Y
10Y
15Y
HALO
21.11.2021 - 28.11.2021

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company offers Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; HYQVIA to treat primary immunodeficiency disorders; Ocrevus (ocrelizumab) for multiple sclerosis; N6LS and cabotegravir to treat HIV; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; Epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat solid tumors; teriparatide injections; OTREXUP, an SC methotrexate injection for severe active rheumatoid arthritis, severe recalcitrant psoriasis, and active polyarticular juvenile idiopathic arthritis; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. The company has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; and Acumen Pharmaceuticals, Inc. The company was founded in 1998 and is headquartered in San Diego, California. Address: 12390 El Camino Real, San Diego, CA, United States, 92130

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

67.00 USD

P/E Ratio

15.33

Dividend Yield

Financials HALO

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures HALO

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+1 015 324 000 USD

Last Year

+829 253 000 USD

Current Quarter

+264 861 000 USD

Last Quarter

+298 008 000 USD

Current Year

+855 907 000 USD

Last Year

+636 892 000 USD

Current Quarter

+216 458 000 USD

Last Quarter

+255 953 000 USD
EBITDA 673 222 976 USD
Operating Margin TTM 53.44 %
Price to Earnings 15.33
Return On Assets TTM 18.50 %
PEG Ratio -2.50
Return On Equity TTM 147.06 %
Wall Street Target Price 67.00 USD
Revenue TTM 1 084 306 048 USD
Book Value 3.92 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 35.20 %
Dividend Yield
Gross Profit TTM 825 883 008 USD
Earnings per share 3.76 USD
Diluted Eps TTM 3.76 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY 55.00 %
Profit Margin 44.76 %

Stock Valuation HALO

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 15.33
Forward PE 11.90
Enterprise Value Revenue 7.13
Price Sales TTM 6.55
Enterprise Value EBITDA 10.97
Price Book MRQ 14.46

Technical Indicators HALO

For 52 Weeks

42.01 USD 70.51 USD
50 Day MA 55.53 USD
Shares Short Prior Month 11 065 499
200 Day MA 55.41 USD
Short Ratio 4.10
Shares Short 10 176 028
Short Percent 12.29 %